Cancel
See Linkedin
Known information
- Founder and CEO of Xione Therapeutics and Opsonix
- Previously Executive Director of Strategic Alliances at MD Anderson Cancer Center
- Former VP of Business Development at Metamark Genetics
- Entrepreneur in Residence at Wyss Institute at Harvard
- Venture Associate at Flagship Pioneering
- Holds a B.S. in Microbiology from the University of Texas at Austin
- Earned a Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard University
About Acrivon Therapeutics
Acrivon Therapeutics develops precision oncology medicines using a proprietary proteomics-based platform, with its lead candidate ACR-368 in a Phase 2 trial for multiple tumor types.
Report inaccurate information